Economic evaluation of long term management strategies for erosive oesophagitis

被引:31
作者
Goeree, R
O'Brien, B
Hunt, R
Blackhouse, G
Willan, A
Watson, J
机构
[1] St Josephs Hosp, Ctr Evaluat Med, Hamilton, ON L8N 4A6, Canada
[2] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada
[3] McMaster Univ, Dept Med, Div Gastroenterol, Hamilton, ON, Canada
关键词
D O I
10.2165/00019053-199916060-00007
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective: To compare the expected costs and outcomes of alternative strategies for the management of patients with erosive oesophagitis. Design: There were 3 components to the overall analytic approach. First, a decision model was constructed to compare expected costs and outcomes of 6 management strategies. Second, principles of quantitative literature review and meta-analysis were used to determine probabilities of clinical events (i.e. oesophagitis healing and recurrence). Finally, principles of cost-effectiveness analysis were used to compare treatment alternatives in terms of dominance and incremental cost effectiveness. The viewpoint for the study was that of a provincial government payer for healthcare over a 1-year period. Main outcome measures and results: Healing rates were significantly higher for proton pump inhibitors (PPI) [p < 0.001]. Recurrence rates were significantly higher for intermittent therapy (placebo) and lower for regular dose PPI (p < 0.001). Maintenance prokinetic agent (PA) is dominated (i.e. more costly and less effective) and step-down maintenance PPI is dominated through principles of extended dominance. The 'efficient frontier' is represented by: maintenance H-2-receptor antagonist (H(2)RA), intermittent PPI, step-down maintenance H2RA and maintenance PPI. Conclusions: The price of H(2)RA is a key factor influencing whether step-down maintenance PPI forms part of, or is contained within, the 'efficient frontier' of long term management for erosive oesophagitis.
引用
收藏
页码:679 / 697
页数:19
相关论文
共 104 条
[11]   EFFECT OF CISAPRIDE ON RELAPSE OF ESOPHAGITIS - A MULTINATIONAL, PLACEBO-CONTROLLED TRIAL IN PATIENTS HEALED WITH AN ANTISECRETORY DRUG [J].
BLUM, AL ;
ADAMI, B ;
BOUZO, MH ;
BRANDSTATTER, G ;
FUMAGALLI, I ;
GALMICHE, JP ;
HEBBELN, H ;
HENTSCHEL, E ;
HUTTEMANN, W ;
SCHUTZ, E ;
VERLINDEN, M .
DIGESTIVE DISEASES AND SCIENCES, 1993, 38 (03) :551-560
[12]   TREATMENT OF REFLUX ESOPHAGITIS - A RANDOMIZED, CONTROLLED EVALUATION OF CIMETIDINE [J].
BREEN, KJ ;
DESMOND, PV ;
WHELAN, G .
MEDICAL JOURNAL OF AUSTRALIA, 1983, 2 (11) :555-558
[13]   REFLUX ESOPHAGITIS THERAPY - SUCRALFATE VERSUS RANITIDINE IN A DOUBLE-BLIND MULTICENTER TRIAL [J].
BREMNER, CG ;
MARKS, IN ;
SEGAL, I ;
SIMJEE, A .
AMERICAN JOURNAL OF MEDICINE, 1991, 91 :S119-S122
[14]  
CARLING L, 1996, GUT, V39, pA182
[15]  
Castell DO, 1996, AM J GASTROENTEROL, V91, P1749
[16]  
CHIBA N, 1993, GASTROENTEROLOGY, V104, pA53
[17]  
CHIBA N, 1993, AM J GASTROENTEROL, V88, P1486
[18]   DOUBLE-BLIND COMPARISON OF OMEPRAZOLE (40 MG OD) VERSUS CIMETIDINE (400 MG QD) IN THE TREATMENT OF SYMPTOMATIC EROSIVE REFLUX ESOPHAGITIS, ASSESSED ENDOSCOPICALLY, HISTOLOGICALLY AND BY 24 H PH MONITORING [J].
DEHN, TCB ;
SHEPHERD, HA ;
COLINJONES, D ;
KETTLEWELL, MGW ;
CARROLL, NJH .
GUT, 1990, 31 (05) :509-513
[19]   AUSTRALIAN CLINICAL-TRIALS OF OMEPRAZOLE IN THE MANAGEMENT OF REFLUX ESOPHAGITIS [J].
DENT, J .
DIGESTION, 1990, 47 :69-71
[20]   OMEPRAZOLE V RANITIDINE FOR PREVENTION OF RELAPSE IN REFLUX ESOPHAGITIS - A CONTROLLED DOUBLE-BLIND TRIAL OF THEIR EFFICACY AND SAFETY [J].
DENT, J ;
YEOMANS, ND ;
MACKINNON, M ;
REED, W ;
NARIELVALA, FM ;
HETZEL, DJ ;
SOLCIA, E ;
SHEARMAN, DJC .
GUT, 1994, 35 (05) :590-598